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Original Article
Impact of sleep apnea on in-hospital outcomes after transcatheter 
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database 2011–2014
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Background: Sleep apnea is associated with worse outcomes following various kinds of surgeries. There 
is a paucity of data on the association of sleep apnea with clinical outcomes after transcatheter aortic valve 
replacement (TAVR). 
Methods: We used National Inpatient Sample (NIS) data 2011–2014 to identify patients undergoing 
TAVR. Association between sleep apnea and in-hospital postoperative outcomes were assessed by 
multivariate logistic regression and 1:1 propensity score matching analyses. 
Results: Of 42,189 patients who received TAVR, 4,605 patients (10.9%) had sleep apnea. Patients with 
sleep apnea were more likely to be younger and male with higher prevalences of hypertension, diabetes 
mellitus, dyslipidemia, chronic kidney disease, pulmonary hypertension and obesity who less frequently 
received transapical access than those without sleep apnea. The group with sleep apnea had less bleeding 
requiring transfusion (8.6% vs. 11.9%, P=0.01) than the counterpart. After adjusting for confounders, 
the presence of sleep apnea was no longer independently associated with any of the studied outcomes 
including all-cause mortality (OR 0.95; 95% CI: 0.64–1.42), stroke (OR 1.08; 95% CI: 0.65–1.81), 
myocardial infarction (OR 0.66; 95% CI: 0.36–1.22), acute respiratory failure (OR 0.94; 95% CI: 0.72–1.23), 
pneumothorax (OR 0.64; 95% CI: 0.26–1.59), vascular complication (OR 0.91; 95% CI: 0.69–1.22), bleeding 
requiring transfusion (OR 0.85; 95% CI: 0.65-1.11), acute kidney injury requiring hemodialysis (OR 0.94; 
95% CI: 0.53–1.66) and permanent pacemaker implantation (OR 1.12; 95% CI: 0.87–1.43). The length and 
cost of hospital stay were not affected by sleep apnea, either. 
Conclusions: With a prevalence of 10.9%, the presence of sleep apnea was not independently associated 
with postoperative in-hospital outcomes in patients undergoing TAVR in NIS data 2011 to 2014.
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Introduction
Surgical aortic valve replacement and transcatheter aortic 
valve replacement (TAVR) are the only effective therapy for 
adult patients with symptomatic severe aortic stenosis to 
offer survival benefit and symptom relief (1). For patients 
with symptomatic severe aortic stenosis who are at high 
or prohibitive risk for surgical aortic valve replacement, 
TAVR is recommended as an alternative treatment based 
on the evidence from PARTNER (Placement of Aortic 
Transcatheter Valves) trial (1-7).
Sleep apnea has been shown to be associated with a wide 
range of cardiopulmonary diseases as well as increased 
postoperative complications (8-11). Approximately 25% of 
adult patients presenting for elective surgery might have 
sleep apnea (12). Accordingly, the American Society of 
Anesthesiologists recommends preoperative evaluation of 
obstructive sleep apnea and subsequent sleep study with 
treatment if necessary (13). 
Given the rising prevalence of sleep apnea (14) and 
rapidly evolving TAVR with its exponentially increasing 
utilization (15), it is imperative to examine the impact of 
sleep apnea on postoperative outcomes of TAVR which may 
have implications for cost-effective preoperative screening 
and perioperative management of sleep apnea. 
Methods
Data source and study population
Data were obtained from the Agency for Healthcare 
Research and Quality Healthcare Cost and Utilization 
Project, National Inpatient Sample (NIS) files between 
2011 and 2014. NIS is the largest publicly available all-
payer inpatient care data in the United States that allows 
national estimates of hospitalization in a given year. De-
identified information for 146,032,189 discharges was 
contained in NIS during the study period. Institutional 
Review Board approval and informed consent were 
not required for this study given the administrative 
de-identified nature of the database. On the basis of 
International Classification of Diseases-9th edition-Clinical 
Modification (ICD-9-CM) codes, each patient data in the 
NIS has ≤25 diagnoses including one principal diagnosis as 
well as ≤15 procedures including one principal procedure 
performed during the same hospitalization. Individual 
patient’s data in NIS also includes Clinical Classification 
Software (CCS) codes which groups multiple ICD-9-CM 
codes into a lesser number of diagnoses and procedures 
categories to facilitate statistical analyses. We identified 
study population, patient comorbidities and procedures 
performed using a combination of ICD-9-CM and CCS 
codes. Patients (aged ≥18 years) who underwent TAVR 
from 2011 through 2014 were identified using ICD-9-CM 
procedure codes of 35.05 and 35.06 recorded in any of the 
15 procedures fields. Patients with data missing mortality 
were excluded. 
Study variables
NIS variables were used to examine patient’s age, gender, 
race, household income quartiles, primary payer, length 
of stay, in-hospital death and discharge location as 
well as hospital’s region, location and teaching status. 
Race was dichotomized into white and nonwhite. The 
severity of comorbidities was defined by using the Deyo 
modification of the Charlson Comorbidity Index where 
higher scores indicate greater burden of comorbidities. 
Sleep apnea was identified with ICD-9-CM codes of 
327.20, 327.21, 327.23, 327.24, 327.26, 327.27, 780.51, 
780.53, 780.57 and 786.03. Similar methodology has been 
previously used to identify patients with sleep apnea (16). 
Noninvasive ventilator use was captured using ICD-9-
CM codes of 93.90 and 93.91 (17). As a postoperative in-
hospital outcome measure, primary endpoint was defined 
as experiencing any complication of all-cause death, stroke 
(ICD 9 codes 997.00, 997.01, 997.02 and CCS code 109) 
and acute myocardial infarction (CCS code 100). Secondary 
endpoint was defined as the occurrence of one or more 
postoperative complications of acute respiratory failure 
(ICD 9 codes 518.81, 518.84, 799.1), pneumothorax (ICD 
9 code 512.1), vascular complications (ICD 9 codes 900-
904, 447, 868.04, 868.14, 998.2, 999.2, 997.7, e870.x, 39.31, 
39.41, 39.49, 39.52, 39.53, 39.56, 39.57, 39.58, 39.59, 
39.79), hemorrhage requiring transfusion (ICD 9 codes 
998.11, 998.12, 285.1 combined with 99.0x), acute kidney 
injury requiring hemodialysis (ICD 9 codes 584.5, 584.6, 
584.7, 584.8, 584.9 combined with 39.95 without principal 
diagnosis of end stage renal disease; 585.6) or permanent 
pacemaker implantation (ICD-9 codes 37.80, 37.81, 37.82, 
37.83). Length of hospital stay was dichotomized at the 75th 
percentile of stay days whereby prolonged length of stay 
was defined as hospital stay exceeding the 75th percentile 
(16,18). Data for race, household income quartile and 
primary payer were missing in 7%, 1.5% and 0.2% of the 
study population, respectively while data for the rest of 
variables were available in 100% of patients. 
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Statistical analysis
For all analyses, we followed the recommendations from 
the Agency for Healthcare Research and Quality by 
using survey specific statements (e.g., SURVEYFREQ, 
SURVEYMEANS). Patient-specific and hospital-specific 
discharge weights were used for inference of national 
estimates. For subpopulation analyses, we used a domain 
analysis for accurate variance calculations. All analyses 
accounted for hospital level clustering of patients and 
the sampling design using CLUSTER and STRATA 
statements, respectively. 
For descriptive analyses, we compared baseline patient 
and hospital characteristics between cohorts with and 
without sleep apnea. Continuous variables are presented 
as means or medians; categorical variables are showed as 
frequencies. For comparison of baseline characteristics, 
either survey specific linear regression or Mann-Whitney U 
test was used for continuous variables and Rao-Scott χ2 test 
was used for categorical variables.
To assess the association between sleep apnea and 
postoperative outcomes, multivariate logistic regression 
models were created for each outcome by forcing sleep 
apnea into a stepwise model selection procedure with 
candidate comorbidity variables using entry and stay 
criteria of a P value less than 0.25 and 0.1, respectively (19). 
Candidate variables were included in the model if the 
variable was significantly associated with outcome (P<0.25) 
in the univariate logistic model, which were from among 
age, gender, race, transapical access, smoking, hypertension, 
diabetes mellitus, dyslipidemia, coronary artery disease, 
previous PCI, previous CABG, pulmonary hypertension, 
congestive heart failure, malignancy, peripheral vascular 
disease, chronic kidney disease, chronic pulmonary disease, 
anemia, coagulopathy, previous stroke, fluid/electrolyte 
disorder, obesity, weight loss, Charlson/Deyo comorbidity 
index, primary payer, household income quartile, hospital 
region, hospital bed size and hospital location/teaching status. 
Use of noninvasive ventilation (NIV) is likely to be either a 
mediator on a causal pathway, if adjusted for, which would 
falsely obscure possible association between sleep apnea and 
postoperative outcomes or a collider, if controlled for, which 
would falsely create spurious association leading to a bias. 
Hence, we did not include the NIV in the main regression 
analyses for adjustment. We used a dummy variable 
adjustment method for missing data for race variable in order 
to preserve the full sample size (20). Multicollinearity was 
examined with VIF statement and all the possible two-way 
interactions were thoroughly tested. Regression model fit was 
assessed by area under the receiver operator characteristic 
curves and Hosmer-Lemeshow χ2 statistic. 
Sensitivity analysis was performed using propensity score 
method to examine the sensitivity of the primary results to 
different statistical approaches. To determine each patient’s 
propensity score of having sleep apnea, a non-parsimonious 
multivariate logistic regression model (c statistic =0.75) was 
used including all covariates used in the primary analysis. 
The propensity score was incorporated as an additional 
covariate in the primary multivariate logistic regression 
model to create Model 2. Furthermore, we performed 1:1 
matching between cohorts with and without sleep apnea 
based on propensity score with a caliper width of 0.2 of 
the standard deviation of the logit of the propensity score 
using greedy algorithm (21). Standardized differences for 
all covariates before and after matching were computed to 
assess the accomplishment of matching where a standardized 
difference of <10% for each covariate after matching is 
suggestive of a successful matching (22). For matched group 
outcome comparisons, conditional logistic regression was 
used with exact test where appropriate. All tests were two-
sided with P values <0.05 indicating statistical significance. 
SAS statistical software, version 9.4 (SAS institute, Cary, 
NC, USA) was used for all statistical analyses. 
Results
Baseline patient characteristics
Of 42,189 TAVR patients, 4,605 (10.9%) had sleep apnea 
and those with obstructive sleep apnea accounted for 85.5% 
of the entire sleep apnea cohort. Prevalence of sleep apnea 
was higher in men than women (Figure 1). Patients with 
sleep apnea were younger, more likely to be male and had 
higher proportions of hypertension, diabetes, dyslipidemia, 
pulmonary hypertension, chronic pulmonary disease and 
obesity with greater Charlson/Deyo comorbidity index 
score who received transapical access less frequently than 
those without sleep apnea (Table 1). NIV was more often 
used in patients with than those without sleep apnea (9.3% 
vs. 2.5%, P<0.0001). 
Postoperative outcomes stratified by sleep apnea
Figure 2 demonstrates observed in-hospital outcomes between 
cohorts with and without sleep apnea. Sleep apnea patients had 
lower incidences of primary endpoint, secondary endpoint, 
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and bleeding requiring transfusion than the counterpart. 
Association between sleep apnea and postoperative outcomes 
Table S1 presents the unadjusted and adjusted association 
between sleep apnea and in-hospital outcomes following 
TAVR. After controlling for covariates, a presence of sleep 
apnea was no longer statistically significantly associated 
with any of the examined in-hospital outcomes (Model 1). 
Multivariate logistic regression adjusting for an additional 
variable of propensity score showed grossly consistent 
results (Model 2). Propensity score matching analyses 
following successful matching (Figure 3) resulted in the 
similar findings (Model 3). Sleep apnea was independently 
associated with neither prolonged hospital stay nor 
discharge disposition. Controlling for the use of NIV 
rendered consistent results (data not shown). Subgroup 
analyses confined to obstructive sleep apnea showed grossly 
consistent findings with the main analyses except for a lower 
likelihood of discharge to home (Table S1). 
Discussion
The main findings of our study are as follows: First, the 
prevalence of sleep apnea in patients undergoing TAVR 
was 10.9%. Second, sleep apnea was not independently 
associated with worse postoperative outcomes following 
TAVR. Third, perioperative provision of NIV in patients 
with sleep apnea was 9.3%.
The prevalence of sleep apnea in TAVR patients is 
similar to the national estimates in the United States (men: 
12.8% vs. 14%, women: 8.9% vs. 5%) that has increased 
over the past two decades in parallel with rising level of 
obesity which is the strongest risk factor for sleep apnea 
(14,23-26). Gender gap of sleep apnea prevalence although 
still significant was smaller in our study than previous 
studies that reported the ratio of men to women with sleep 
apnea to be 2–3 to 1. It is noteworthy that sleep apnea is 
more prevalent in patients undergoing TAVR than those 
receiving orthopedic, spinal, general or vascular surgeries 
based on analyses of national data (16,27,28). Our findings 
compare to the known association between sleep apnea and 
multiple comorbidities including hypertension, diabetes 
mellitus, dyslipidemia, chronic kidney disease, pulmonary 
hypertension and obesity (26,29-33). 
Patients with sleep apnea undergoing surgery may be 
at increased risk for postoperative complications since 
anesthesia or analgesia could cause pharyngeal relaxation 
leading to exacerbation of apnea. A growing body of 
literature suggests the potential link between sleep apnea 
and worse postoperative outcomes following cardiac as 
well as non-cardiac surgeries (9-11,16,27,34). Memtsoudis 
et al. found a significant independent association between 
sleep apnea and cardiopulmonary complications after 
both orthopedic and general surgeries (16,27). Kaw et al. 
reported an increased risk for postoperative complications 
in patients with sleep apnea undergoing open heart 
surgeries (9). Our findings focused on patients undergoing 
TAVR are in contrast to the aforementioned results from 
other surgeries. The observed incidences of primary 
endpoint and secondary endpoint including bleeding were 
lower, despite their higher burden of comorbidities, in 
patients with than those without sleep apnea. There are 
several plausible explanations for these observations. We 
speculate higher postoperative complication rates in patients 
without sleep apnea may have been partly contributed by 
greater utilization of transapical access for TAVR than the 
counterpart. In numerous studies, transapical access for 
TAVR was found to be associated with worse outcomes 
compared with transfemoral access (35-37). In addition, 
the higher proportion of women in the group without 
sleep apnea may explain the higher bleeding complications 
as female gender has been shown to be a predictor of 
bleeding complications after TAVR in previous studies 
(38-42). However, after adjusting for all potential 
confounding factors available in the study, the presence of 
sleep apnea no longer remained statistically significantly 
associated with any of  the  examined in-hospi ta l 
postoperative outcomes of TAVR. This finding suggests 
that observed differences in postoperative outcomes 
Men
12.8
8.9
P<0.0001(%)
14
12
10
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Figure 1 Prevalence of sleep apnea by gender among transcatheter 
aortic valve replacement (TAVR) patients.
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Table 1 Baseline characteristics of patients with and without sleep apnea
Baseline characteristics Overall Without sleep apnea Sleep apnea P value
Number of patients, (%) 42,189 37,584 (89.1%) 4,605 (10.9%)
Age (years), mean ± SE 81.1±0.1 81.7±0.1 76.9±0.3 <0.0001
Age group (years) <0.0001
18–49 250 (0.6%) 216 (0.6%) 35 (0.8%)
50–64 1,882 (4.5%) 1,487 (4.0%) 394 (8.6%)
65–79 11,750 (27.9%) 9,577 (25.5%) 2,173 (47.2%)
80– 28,308 (67.1%) 26,305 (70.0%) 2,003 (43.5%)
Women 20,074 (47.6%) 18,296 (48.7%) 1,778 (38.6%) <0.0001
Race 0.41
White 34,229 (87.2%) 30,469 (87.1%) 3,760 (88.0%)
Nonwhite 5,025 (12.8%) 4,513 (12.9%) 511 (12.0%)
Smoking history 1,286 (3.0%) 1,166 (3.1%) 120 (2.6%) 0.41
Hypertension 34,375 (81.5%) 30,503 (81.2%) 3,872 (84.1%) 0.02
Diabetes mellitus 14,136 (33.5%) 11,832 (31.5%) 2,304 (50.0%) <0.0001
Dyslipidemia 27,144 (64.3%) 23,992 (63.8%) 3,152 (68.4%) 0.01
Chronic kidney disease 15,868 (37.6%) 13,945 (37.1%) 1,923 (41.8%) 0.01
Pulmonary hypertension 9,446 (22.4%) 8,155 (21.7%) 1,291 (28.0%) <0.0001
Congestive heart failure 31,196 (73.9%) 27,758 (73.9%) 3,438 (74.7%) 0.61
Peripheral vascular disease 10,141 (24.0%) 8,943 (23.8%) 1,198 (26.0%) 0.13
Coronary artery disease 30,109 (71.4%) 26,802 (71.3%) 3,307 (71.8%) 0.75
Previous PCI 7,903 (18.7%) 7,024 (18.7%) 879 (19.1%) 0.77
Previous CABG 9,388 (22.2%) 8,362 (22.2%) 1,026 (22.3%) 0.98
Chronic pulmonary disease 11,573 (27.4%) 9,786 (26.0%) 1,787 (38.8%) <0.0001
Anemia 11,158 (26.4%) 9,981 (26.6%) 1,177 (25.6%) 0.51
Coagulopathy 10,059 (23.8%) 9018 (24.0%) 1,041 (22.6%) 0.31
History of stroke 4,280 (10.1%) 3,838 (10.2%) 442 (9.6%) 0.55
Malignancy 6,297 (14.9%) 5,688 (15.1%) 608 (13.2%) 0.11
Fluid and electrolyte disorder 11,273 (26.7%) 10,140 (27.0%) 1,132 (24.6%) 0.17
Obesity 5,919 (14.0%) 4,027 (10.7%) 1,893 (41.1%) <0.0001
Weight loss 2,165 (5.1%) 2,030 (5.4%) 134 (2.9%) 0.003
Charlson/Deyo comorbidity index, median (IQR) 2.3 (1.1–3.6) 2.3 (1.0–3.6) 2.7 (1.5–4.0) <0.0001
Noninvasive ventilation 1,378 (3.3%) 949 (2.5%) 429 (9.3%) <0.0001
Transapical access 8,523 (20.2%) 7,746 (20.6%) 777 (16.9%) 0.01
Mean household income <0.0001
1st quartile 8,617 (20.8%) 7,893 (21.4%) 724 (16.0%)
2nd quartile 10,300 (24.8%) 8,976 (24.3%) 1,324 (29.3%)
3rd quartile 10,660 (25.7%) 9,342 (25.3%) 1,318 (29.1%)
4th quartile 11,890 (28.7%) 10,731 (29.0%) 1,159 (25.6%)
Table 1 (continued)
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Table 1 (continued)
Baseline characteristics Overall Without sleep apnea Sleep apnea P value
Primary payer 0.004
Medicare/medicaid 38,415 (91.2%) 34,364 (91.6%) 4,051 (88.2%)
Private including HMO 2,960 (7.0%) 2,517 (6.7%) 444 (9.7%)
Self-pay/no charge/other 750 (1.8%) 650 (1.7%) 100 (2.2%)
Hospital region 0.001
Northeast 10,867 (25.8%) 9,909 (26.4%) 958 (20.8%)
Midwest or North Central 9,314 (22.1%) 8,086 (21.5%) 1,228 (26.7%)
South 14,447 (34.2%) 12,809 (34.1%) 1,638 (35.6%)
West 7,561 (17.9%) 6,781 (18.0%) 781 (16.9%)
Hospital bed size 0.12
Small 1,995 (4.7%) 1,815 (4.8%) 180 (3.9%)
Medium 6,787 (16.1%) 5,966 (15.9%) 821 (17.8%)
Large 33,408 (79.2%) 29,803 (79.3%) 3,604 (78.3%)
Hospital location/teaching status 0.30
Rural 305 (0.7%) 260 (0.7%) 45 (1.0%)
Urban non-teaching 4,312 (10.2%) 3,893 (10.4%) 420 (9.1%)
Urban teaching 37,572 (89.1%) 33,431 (89.0%) 4,141 (89.9%)
Cost of hospitalization ($), mean ± SE [median] 57,901±648 [51,295] 58,109±661 [51,341] 56,200±1,211 [50,869] 0.36
Length of stay, mean ± SE (median) 8.1±0.1 (5.4) 8.1±0.1 (5.5) 7.5±0.2 (5.4) 0.10
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; HMO, health maintenance organization.
Figure 2 In-hospital outcomes after transcatheter aortic valve replacement (TAVR) in patients with and without sleep apnea.
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between patients with and without sleep apnea were driven 
by confounders. It is reassuring that in-hospital outcomes 
are comparable in patients undergoing TAVR regardless of 
the presence of sleep apnea after adjusting for confounders. 
Guidelines from the American Society of Anesthesiologists 
recommend that patients with sleep apnea on preoperative 
NIV continue the therapy after surgery (13). Previous studies 
demonstrated the low frequency of provision of CPAP in 
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the hospital setting (17,43). In our study, utilization of NIV 
for patients with sleep apnea was only 9.3% although higher 
than patients without sleep apnea. The lower rate of NIV 
use would suggest possible room for quality improvement 
in perioperative management for patients with sleep apnea 
undergoing TAVR despite currently lacking evidence of the 
benefit of NIV use on postoperative outcomes. 
This is the first study, of which we are aware, that 
examined the association between sleep apnea and in-
hospital outcomes after TAVR with a large population. 
This study is based on a large real-world data which confers 
generalizability of the findings. Also, use of different 
statistical methodologies for the analyses would consolidate 
the internal validity of our study. 
Several important factors need to be noted when 
interpreting the result of our study. First, the logistic 
EuroScore and Society of Thoracic Surgeons score were not 
available in NIS data for adjustment although multivariate 
regression and propensity score matching achieved 
adequate balance including Charlson/Deyo index between 
the two study cohorts. Second, data on types of anesthesia 
used for TAVR was not available. General anesthesia could 
potentially interact with sleep apnea on postoperative 
outcomes although the outcomes of both general 
anesthesia and local anesthesia were comparable after 
TAVR (44) that would preclude the type of anesthesia from 
biasing the association as a confounder. Third, potential 
misclassification of sleep apnea should be considered given a 
large proportion of sleep apnea remains undiagnosed when 
patients present to surgery. Preexisting undiagnosed sleep 
apnea was prevalent in more than 80% of surgical patients 
(12,45). This potential non-differential misclassification 
of sleep apnea could have biased the possible association 
between sleep apnea and postoperative outcomes toward 
the null. Nevertheless, the absence of the independent 
association between sleep apnea and TAVR outcomes in 
our study is still convincing given that previous studies with 
the even lower prevalence of sleep apnea still demonstrated 
worse outcomes after other surgeries in patients with sleep 
apnea (16,27). Fourth, no detailed clinical information such 
as post-TAVR aortic regurgitation, site of bleeding and 
postoperative hemodynamic performance of the valve were 
available for study. Fifth, the severity of sleep apnea was not 
accounted for in the absence of information on the apnea-
hypopnea index in NIS data.
Conclusions
In patients undergoing TAVR for the treatment of 
symptomatic severe aortic stenosis, the prevalence of sleep 
apnea was 10.9%, and the presence of sleep apnea was not 
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Figure 3 Standardized differences between transcatheter aortic valve replacement (TAVR) patients with and without sleep apnea.
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independently associated with postoperative in-hospital 
outcomes in the NIS data of the years from 2011 to 2014.
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Table S1 Association between sleep apnea and in-hospital outcomes following TAVR (non-sleep apnea cohort as reference)
In-hospital outcomes Unadjusted OR (95% CI) P value
Adjusted OR  
(95% CI); Model 1
P value
Adjusted OR  
(95% CI); Model 2
P value
Adjusted OR (95% CI); 
Model 3
P value
Unadjusted OR 
(95% CI)
P value
Adjusted OR  
(95% CI)
P value
Primary endpoints 0.76 (0.58–0.99) 0.049 0.93 (0.69–1.25) 0.61 1.03 (0.76–1.39) 0.85 1.06 (0.72–1.55) 0.77 0.74 (0.56–0.99) 0.045 0.90 (0.65–1.24) 0.51 
All-cause mortality 0.75 (0.52–1.09) 0.13 0.95 (0.64–1.42) 0.81 0.98 (0.66–1.46) 0.93 0.97 (0.57–1.62) 0.89 0.73 (0.49–1.10) 0.13 0.92 (0.60–1.41) 0.69
Stroke 0.78 (0.49–1.25) 0.30 1.08 (0.65–1.81) 0.77 1.13 (0.67–1.93) 0.64 1.25 (0.65–2.41) 0.51 0.83 (0.51–1.35) 0.46 1.16 (0.67–2.00) 0.60
Myocardial infarction 0.64 (0.37–1.11) 0.11 0.66 (0.36–1.22) 0.18 0.77 (0.41–1.43) 0.41 0.81 (0.39–1.69) 0.58 0.52 (0.27–1.01) 0.05 0.52 (0.25–1.09) 0.09
Secondary endpoints 0.86 (0.75–0.99) 0.04 0.92 (0.79–1.07) 0.28 0.93 (0.79–1.09) 0.35 0.98 (0.80–1.20) 0.83 0.93 (0.80–1.07) 0.31   0.99 (0.84–1.16) 0.87 
Acute respiratory failure 0.94 (0.73–1.20) 0.61 0.94 (0.72–1.23) 0.65 0.92 (0.69–1.22) 0.56 1.20 (0.84–1.72) 0.32 0.95 (0.73–1.23) 0.69 0.94 (0.71–1.24) 0.66
Pneumothorax 0.45 (0.18–1.09) 0.08 0.64 (0.26–1.59) 0.33 0.65 (0.25–1.65) 0.36 0.46 (0.12–1.42) 0.21 0.53 (0.22–1.30) 0.16 0.78 (0.31–1.93) 0.59
Vascular complication 0.83 (0.63–1.10) 0.20 0.91 (0.69–1.22) 0.54 0.94 (0.70–1.26) 0.68 0.71 (0.49–1.02) 0.06 0.88 (0.65–1.18) 0.38 0.97 (0.71–1.31) 0.82
Bleeding requiring transfusion 0.70 (0.55–0.90) 0.01 0.85 (0.65–1.11) 0.22 0.86 (0.65–1.12) 0.26 0.84 (0.61–1.15) 0.26 0.73 (0.56–0.94) 0.01 0.87 (0.66–1.16) 0.34
Acute kidney injury requiring 
hemodialysis
0.95 (0.56–1.64) 0.86 0.94 (0.53–1.66) 0.82 0.99 (0.57–1.71) 0.96 0.83 (0.42–1.65) 0.60 1.05 (0.60–1.85) 0.86 1.00 (0.54–1.83) 0.99
Permanent pacemaker implantation 1.13 (0.90–1.42) 0.30 1.12 (0.87–1.43) 0.39 1.11 (0.86–1.44) 0.41 1.25 (0.92–1.71) 0.16 1.22 (0.97–1.54) 0.09 1.21 (0.94–1.55) 0.14
Prolonged length of stay  
(length of stay ≥9 days)
0.89 (0.75–1.05) 0.15 0.98 (0.82–1.17) 0.78 0.98 (0.81–1.17) 0.80 0.96 (0.78–1.19) 0.71 1.01 (0.86–1.20) 0.88 1.11 (0.92–1.34) 0.28
Discharge to home 1.16 (1.01–1.34) 0.04 0.87 (0.74–1.03) 0.11 0.88 (0.74–1.04) 0.13 1.00 (0.82–1.23) 1.00 1.09 (0.94–1.27) 0.24 0.83 (0.69–0.98) 0.03
Model 1 was adjusted for candidate covariates that had significant univariate association with outcomes (P<0.25) from among age, gender, trans–apical approach, white race, smoking, hypertension, diabetes mellitus, dyslipidemia, previous percutaneous 
coronary intervention, previous coronary artery bypass grafting, pulmonary hypertension, congestive heart failure, malignancy, peripheral vascular disease, chronic kidney disease, chronic pulmonary disease, Charlson/Deyo comorbidity scores, anemia, 
coagulopathy, previous stroke, fluid/electrolytes disorder, obesity, weight loss, primary payer, income quartile, hospital region, hospital bed size and hospital location/teaching status. Mode 2 was adjusted for propensity score in addition to the same 
covariates from Model 1. Model 3 was adjusted for covariates by using 1:1 propensity score matching. C-statistics of multivariate regression Model 1 for primary endpoints, mortality, stroke, myocardial infarction, secondary endpoints, acute respiratory 
failure, pneumothorax, vascular complication, bleeding, acute kidney injury and permanent pacemaker implantation were 0.73, 0.73, 0.82, 0.75, 0.63, 0.73, 0.70, 0.61, 0.67, 0.88 and 0.60, respectively. All P values of Hosmer-Lemeshow goodness of fit test for 
each outcome were >0.05. There was no multicollinearity detected (all tolerance >0.4) and no two way interaction with sleep apnea was found for each outcome. TAVR, transcatheter aortic valve replacement.
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